ReviewFrontiers in immunology2020
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data.Frontiers in immunology · 2025Pooled it
- Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials.Scientific reports · 2023Pooled it
- Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Trial
- Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases.Cancer medicine · 2026Review
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- Epithelial YPEL3 Modulates CD8Cancer science · 2026Article
- GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.Nature cancer · 2026Article
- SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8Nature communications · 2026Article
- Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.JAMA network open · 2026Article
- Article
- Revised tumor burden score for prognostic stratification in metastatic colorectal cancer patients receiving immunotherapy: a retrospective study.The oncologist · 2026Observational
- HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody.NPJ vaccines · 2026Article
- Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer.Scientific reports · 2026Article
- Th17-driven CD8Cell death & disease · 2026Article
- Alterations in PD-L1Medicina (Kaunas, Lithuania) · 2026Article
- Evaluation of Trilysine-Cross-Linked Gellan Gum for Intratumoral Delivery of Anti-PD-1 in a Colorectal Cancer Mouse Tumor Model.ACS biomaterials science & engineering · 2026Article
- CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming.Cancer immunology research · 2026Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but its efficacy has been variable across patients. Biomarkers to predict such differential response to immunotherapy include cytotoxic T lymphocyte infiltration, tumor mutational burden, and microsatellite instability. A growing number of studies also suggest that baseline tumor burden, or tumor size, predicts response to immunotherapy. In this review, we discuss the changes in immune profile and therapeutic responses that occur with increasing tumor size. We also overview therapeutic approaches to reduce tumor burden and favorably modulate the immune microenvironment of larger tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.